Clinical performance and effect of pre‐analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology

Abstract

Background: Plasma phosphorylated tau 217P (pTau217) is a promising biomarker for aiding in the detection of amyloid pathology. Studies suggest the plasma pTau217 to plasma amyloid‐β (1–42) (Aβ42) ratio may outperform pTau217 alone.